Based on these findings, we suggest that it could be beneficial to test patients with a range of motor neuron diseases, including dHMN, atypical and typical ALS, as well as (distal) myopathy and MSP phenotypes, for pathogenic HNRNPA1 variants. Here, HNRNPA1 is linked to motor neuron disorder.